Aza-pyridone compounds and uses thereof
AssigneeAlios BioPharma, Inc.
InventorsRobert Than Hendricks, Leonid Beigelman, David Bernard Smith, Antitsa Dimitrova Stoycheva
Life of this patent
Estimating the term…
Abstract
Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compound. Examples of an orthomyxovirus viral infection include an influenza infection.
Claims39
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) has the structure:
- wherein:
- R1 is selected from the group consisting of hydrogen, an unsubstituted C1-4 alkyl, an optionally substituted heterocyclyl, —C(═O)Y1, —C(═O)—O—Y1, —(CH2)—O—C(═O)—Y1, —(CH2)—O—C(═O)—O—Y1, —(CHCH3)—O—C(═O)—Y1 and —(CHCH3)—O—C(═O)—O—Y1;
- R2 is selected from the group consisting of hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(C1-6 alkyl), an optionally substituted aryl(C1-6 alkyl), an optionally substituted heteroaryl(C 1-6 alkyl) and an optionally substituted heterocyclyl(C1-6 alkyl);
- R3a and R3b are independently hydrogen or an optionally substituted C1-4 alkyl;
- R4 is selected from the group consisting of:
- R6A and R6B are each hydrogen, each fluoro or each chloro;
- or
- R6A and R6B are independently hydrogen, an unsubstituted C1-4 alkyl or an unsubstituted C2-4 alkynyl, provided that at least one of R6A and R6B is an unsubstituted C1-4 alkyl or an unsubstituted C2-4 alkynyl;
- R6C is an optionally substituted aryl or an optionally substituted heteroaryl;
- R6D is an optionally substituted heteroaryl;
- R6E and R6F are each hydrogen or each fluoro;
- R6G and R6H are each fluoro or each chloro;
- R5 is selected from the group consisting of hydrogen, halogen, —CN, an optionally substituted C1-6 alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, —CH2OH, —CH(Y2)(OH) and —C(O)Y2;
- Y1 and Y2 are independently selected from the group consisting of an optionally substituted C1-6 alkyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, a mono-substituted amino group, a di-substituted amino and —C(R7)2NHR8;
- and
- each R7 and R8 are independently hydrogen or an optionally substituted C1-4 alkyl;
- and
- provided that:
- when R4 is
- wherein R6A and R6B are each hydrogen, and R2 is hydrogen, CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH(CH3)2, —CH(CH2CH3)2, —CH2CH(CH3)2, —CH(CH3)CF3, —CH2—(C3-cyclopropyl), tetrahydro-2H-pyran, —CH2CH2OH, —CH2CH2OCH3 or —C(CH3)2CH2OCH3;
- then R1 is not hydrogen, —C(═O)CH3, —C(═O)CH(CH3)2, —C(═O)CH2CH(CH3)2, —C(═O)—(C5-6-cycloalkyl), —C(═O)-(tetrahydro-2H-pyran), —C(═O)—O—CH(CH3)2, —C(═O)—O—CH2CH(CH3)2, —CH2—O—C(═O)CH(CH3)(NH2), —CH2—O—C(═O)CH(CH(CH3)2)(NH2) or —CH2—O—C(═O)C((CH3)2)(NH2);
- when R4 is
- wherein R6A and R6B are each fluoro, and R2 is —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2—(C3-cyclopropyl), -unsubstituted benzyl, —CH2CH2OH or —CH2CH2OCH3;
- then R1 is not hydrogen, —CH2CH3, —C(═O)CH3, —C(═O)CH(CH3)2, —CH2—O—C(═O)—O-(phenyl substituted with methyl and nitro), —CH2—O—C(═O)—NH—CH2CH2-(morpholine), —CH2—O—C(═O)CH(CH(CH3)2)(NH2) or —CH2—O—C(═O)NH(CH3);
- when R4 is
- wherein R6A and R6B are each chloro, and R2 is —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2—(C3-cyclopropyl), —CH2CH2OH or —CH2CH2OCH3;
- then R1 is not hydrogen or —C(═O)CH(CH3)2;
- when R4 is
- wherein one of R6A and R6B is an unsubstituted C1-4 alkyl;
- then R1 is not hydrogen;
- when R4 is
- wherein R6E and R6F are each hydrogen, and R2 is —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2—(C3-cyclopropyl), an unsubstituted benzyl, —CH(CH3)CF3, —CH2CH2OH or —CH2CH2OCH3;
- then R1 is not hydrogen or —C(═O)CH(CH3)2;
- when R4 is
- wherein R6E and R6F are each fluoro, and R2 is —CH3, —CH2CH3, —CH2CH2CH3, —CH2CH2CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2—(C3-cyclopropyl), —CH2CH2OH or —CH2CH2OCH3;
- then R1 is not hydrogen or —C(═O)CH(CH3)2;
- when R4 is
- wherein R6C is pyrazolyl and R6D is unsubstituted phenyl;
- then R6C is a di-substituted pyrazolyl;
- wherein when R4 is
- wherein R6C is an optionally substituted imidazolyl or an optionally substituted pyridinyl;
- then R6D is not an optionally substituted phenyl;
- and
- when R4 is
- wherein R6G and R6H are each fluoro or each chloro, and R2 is —CH3;
- then R1 is not hydrogen.
A Compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt of any of the foregoing.
Dependencies are inferred from the claim text.